کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2100145 1546174 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Optimal dose and schedule of consolidation in AML: Is there a standard?
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Optimal dose and schedule of consolidation in AML: Is there a standard?
چکیده انگلیسی

Approximately 35%–40% of younger adults with acute myeloid leukemia (AML) can be cured using higher doses of cytosine arabinoside (ara-C) as post remission consolidation. Earlier studies focused on higher doses of 3 gms/m2, but since then numerous studies evaluating differences in dose, schedule, number of courses, and the addition of other agents, suggest that an intermediate-dose of ara-C may offer the greatest benefit to most patients with less toxicity than with higher dose regimens. In retrospect, this was predictable by the cellular pharmacology of ara-C. Perhaps most importantly, the overall outcome has not changed in the past 2-3 decades, indicating that the limits of available chemotherapy have been defined for AML. This review examines studies that have established the various dosing options and considers whether there is a true standard for post remission therapy for patients with AML.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Haematology - Volume 27, Issues 3–4, September–December 2014, Pages 259–264
نویسندگان
,